Pleural Diseases Market Report 2026

Pleural Diseases Market Overview

• Pleural Diseases market size has reached to $5.21 billion in 2025 • Expected to grow to $7.35 billion in 2030 at a compound annual growth rate (CAGR) of 7.1% • Growth Driver: Rising Prevalence Of Infectious Diseases Driving The Growth Of The Market Due To Increasing Risk Of Infections Leading To Pleural Complications • Market Trend: Advancing Treatment Accessibility With Ready-To-Use Injectable Innovations • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pleural Diseases Market?

Pleural diseases refer to a group of conditions that affect the pleura, which is the double-layered membrane surrounding the lungs. These diseases can involve inflammation, infection, or other pathological pleural changes. Pleural diseases cause chest pain, shortness of breath, coughing, and difficulty breathing and are often diagnosed with imaging tests such as chest X-rays or CT scans. The main disease types of pleural diseases are pleurisy, pleural effusion, pneumothorax, mesothelioma, and others. Pleurisy, characterized by inflammation of the pleura, causes sharp chest pain and is linked to infections or autoimmune disorders. Treatment options encompass medications, thoracentesis, pleurodesis, minimally invasive procedures, and surgical interventions. Diagnostics involve imaging techniques, molecular diagnostics, thoracoscopy, and pleuroscopy. These services are utilized in hospitals, clinics, diagnostic centers, and research or academic institutions.

What Is The Pleural Diseases Market Growth Forecast?

The pleural diseases market size is expected to see strong growth in the next few years. It will grow to $7.35 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increasing investments in early cancer detection, rising demand for minimally invasive diagnostics, expansion of precision medicine approaches, growing focus on outpatient respiratory care, advancements in pleural disease therapeutics. Major trends in the forecast period include increasing adoption of advanced imaging diagnostics, rising use of minimally invasive pleural interventions, growing integration of molecular diagnostic tools, expansion of early disease detection programs, enhanced focus on personalized treatment approaches.

Global Pleural Diseases Market Segmentation

1) By Disease Type: Pleurisy, Pleural Effusion, Pneumothelioma, Mesothelioma, Other Disease Types 2) By Treatment Modalities: Medications, Thoracentesis And Pleurodesis, Minimally Invasive Interventions, Surgical Interventions 3) By Diagnostic Tools: Imaging Techniques, Molecular Diagnostics, Thoracoscopy, Pleuroscopy 4) By End User: Hospitals And Clinics, Diagnostic Centers, Research And Academic Institutions Subsegments: 1) By Pleurisy: Acute Pleurisy, Chronic Pleurisy, Infectious Pleurisy, Non-infectious Pleurisy 2) By Pleural Effusion: Transudative Pleural Effusion, Exudative Pleural Effusion, Malignant Pleural Effusion, Parapneumonic Pleural Effusion, Hemothorax, Chylothorax 3) By Pneumothelioma: Primary Pneumothelioma, Secondary Pneumothelioma (Metastatic), Localized Pneumothelioma, Diffuse Pneumothelioma 4) By Mesothelioma: Pleural Mesothelioma, Benign Pleural Tumors, Pleural Thickening Disorders, Pleural Plaques 5) By Other Disease Types: Empyema, Fibrothorax, Pneumothorax, Lung Cancer, Tuberculosis-Related Pleural Disease, Sarcoidosis

What Is The Driver Of The Pleural Diseases Market?

The increasing prevalence of infectious diseases are expected to drive the growth of the pleural diseases market going forward. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites. Environmental changes to human behavior and advancements in global travel influence the increasing prevalence of infectious diseases. Infectious diseases such as bacterial pneumonia, tuberculosis, or viral infections can cause pleural disease by triggering inflammation, infection, or fluid accumulation in the pleural cavity. For instance, in January 2023, according to the National Library of Medicine, a US-based medical library for research and information, infectious diseases account for over 52 million deaths annually, placing half of the global population at risk. Further, each year, approximately 14 million children under the age of five die, with 70% of these deaths attributed to diseases that could be prevented through vaccination. Therefore, the increasing prevalence of infectious diseases drives the growth of the pleural diseases industry.

Key Players In The Global Pleural Diseases Market

Major companies operating in the pleural diseases market are Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, GSK plc, Astrazeneca plc, Koninklijke Philips N.V., Becton Dickinson and Company, Boehringer Ingelheim International GmbH, Sanofi SA, Penn Medicine, Henry Ford Health, Dragerwerk AG, Emory Healthcare, Boston Medical Center, Cook Medical, WakeMed, Weill Cornell Medicine, Fox Chase Cancer Center, B. Braun SE, Bicakcilar, Redax S.p.a, Rocket Medical

Global Pleural Diseases Market Trends and Insights

Major companies operating in the pleural diseases market are focusing on developing innovative treatment options, such as developing ready-to-use injectable treatments, to improve convenience, reduce preparation time, and minimize dosing errors. Ready-to-use injectable treatments are pre-formulated, pre-diluted medications that require no reconstitution or mixing before administration, ensuring accuracy, convenience, and reduced preparation time. For instance, in April 2024, Amneal Pharmaceuticals, a US-based pharmaceutical company, launched PEMRYDI RTU, the first ready-to-use version of pemetrexed for injection. This helps people with pleural diseases by providing a convenient, ready-to-use treatment that eliminates the need for reconstitution or dilution, reduces preparation time, minimizes the risk of dosing errors, and improves access to effective therapy for conditions like malignant pleural mesothelioma.

What Are Latest Mergers And Acquisitions In The Pleural Diseases Market?

In October 2023, Aileron Therapeutics Inc., a US-based biopharmaceutical company, acquired Lung Therapeutics Inc. for an undisclosed amount. This acquisition strengthens the pipeline by integrating LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusions (LPEs), expanding the focus on orphan pulmonary and fibrosis diseases. Lung Therapeutics Inc. is a US-based biopharmaceutical company developing innovative peptide drugs targeting fibrosis and rare pulmonary conditions.

Regional Outlook

North America was the largest region in the pleural diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pleural Diseases Market?

The pleural diseases market consist of revenues earned by entities by providing services such as diagnostic, pleurodesis, respiratory therapy, rehabilitation, and biopsy procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The pleural diseases market also includes sales of antibiotics, chemotherapeutic agents, thoracentesis kits, chest tubes and drainage systems, and pleural biopsy needles. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pleural Diseases Market Report 2026?

The pleural diseases market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pleural diseases industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.